Aescap

News

WELCOME

Investing in the most promising life sciences companies

Aescap I started investing in private life sciences companies late 2006 from a €100 million fund. The fund is now in a divestment mode and so far has successfully taken Biocartis public on the Euronext stock exchange and has sold EOS and Actogenix to two Nasdaq listed biotech companies in the US.  The Fund is supported by the European Communities Growth and Employment Initiative, MAP - ETF Start up Facility. 

Aescap2.0, a new initiave, is a mutual fund investing in the most promising public life sciences / biotech companies. The fund mainly invests is small/mid cap companies in the EU and US. 

For more information do not hesistate to contact us. Call managing partner Patrick Krol at +31 20 570 29 40.